In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Development of hypoxia-targeted therapies has stimulated the search for clinically applicable noninvasive markers of tumour hypoxia. Here, we describe the validation of [(18)F]fluoroetanidazole ([(18)F]FETA) as a tumour hypoxia marker by positron emission tomography (PET). Cellular transport and retention of [(18)F]FETA were determined in vitro under air vs nitrogen. Biodistribution and metabolism of the radiotracer were determined in mice bearing MCF-7, RIF-1, EMT6, HT1080/26.6, and HT1080/1-3C xenografts. Dynamic PET imaging was performed on a dedicated small animal scanner. [(18)F]FETA, with an octanol-water partition coefficient of 0.16+/-0.01, was selectively retained by RIF-1 cells under hypoxia compared to air (3.4- to 4.3-fold at 60-120 min). The radiotracer was stable in the plasma and distributed well to all the tissues studied. The 60-min tumour/muscle ratios positively correlated with the percentage of pO(2) values <5 mmHg (r=0.805, P=0.027) and carbogen breathing decreased [(18)F]FETA-derived radioactivity levels (P=0.028). In contrast, nitroreductase activity did not influence accumulation. Tumours were sufficiently visualised by PET imaging within 30-60 min. Higher fractional retention of [(18)F]FETA in HT1080/1-3C vs HT1080/26.6 tumours determined by dynamic PET imaging (P=0.05) reflected higher percentage of pO(2) values <1 mmHg (P=0.023), lower vessel density (P=0.026), and higher radiobiological hypoxic fraction (P=0.008) of the HT1080/1-3C tumours. In conclusion, [(18)F]FETA shows hypoxia-dependent tumour retention and is, thus, a promising PET marker that warrants clinical evaluation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects
Hockel, M., & Vaupel, P. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.4.266 · Cited by 2,662
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J. (1996) · Nature · doi:10.1038/379088a0 · Cited by 2,300 · cited 1×
“Detection of hypoxia is important because hypoxia is a powerful trigger for gene expression and thus clonal selection of a more aggressive phenotype, for example, diminished apoptotic potential (Gräber et al, 1996; Koong et al, 2000).”
BackgroundIntratumoral pO2 predicts survival in advanced cancer of the uterine cervix
Höckel, M., Knoop, C., Schlenger, K., Vorndran, B., Bauβnann, E., Mitze, M., Knapstein, P. G., & Vaupel, P. (1993) · Radiotherapy and Oncology · doi:10.1016/0167-8140(93)90025-4 · Cited by 809
Cited by
Tatum, J. L. (2006) · International Journal of Radiation Biology · doi:10.1080/09553000601002324 · Cited by 620
Imaging hypoxia to improve radiotherapy outcome
Horsman, M. R., Mortensen, L. S., Petersen, J. B., Busk, M., & Overgaard, J. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.171 · Cited by 614
Krohn, K. A., Link, J. M., & Mason, R. P. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.045914 · Cited by 506
The Influence of Comorbidities on Overall Survival Among Older Women Diagnosed With Breast Cancer
Patnaik, J. L., Byers, T., DiGuiseppi, C., Denberg, T. D., & Dabelea, D. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr188 · Cited by 283
Riedl, C. C., Brader, P., Zanzonico, P. B., Chun, Y. S., Woo, Y., Singh, P., Carlin, S., Wen, B., Ling, C. C., Hricak, H., et al. (2008) · Radiology · doi:10.1148/radiol.2482071421 · Cited by 41
Metadata
- Authors
- Barthel, H., Wilson, H., Collingridge, D. R., Brown, G., Osman, S., Luthra, S. K., Brady, F., Workman, P., Price, P. M., & Aboagye, E. O.
- Venue
- British Journal of Cancer
- Published
- 2004-05-11
- Volume
- 90
- Issue
- 11
- Pages
- 2232-2242
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2003668572
- Cited by
- 92
- References
- 3
- FWCI
- 3.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.